NASDAQ: NAGE
Niagen Bioscience Inc Stock

$2.95-0.03 (-1.01%)
Updated Sep 29, 2026
NAGE Price
$2.95
Fair Value Price
-$0.48
Market Cap
$233.42M
52 Week Low
$2.87
52 Week High
$9.28
P/E
14.75x
P/B
2.83x
P/S
1.96x
PEG
N/A
Dividend Yield
N/A
Revenue
$129.08M
Earnings
$15.99M
Gross Margin
64.2%
Operating Margin
13.19%
Profit Margin
12.4%
Debt to Equity
0.29
Operating Cash Flow
$6M
Beta
1.52
Next Earnings
Nov 3, 2026
Ex-Dividend
N/A
Next Dividend
N/A

NAGE Overview

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine NAGE's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
NAGE
Ranked
#73 of 466

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$9.78A
$8.05A
$365.27A
View Top Biotech Stocks

Be the first to know about important NAGE news, forecast changes, insider trades & much more!

NAGE News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NAGE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NAGE ($2.95) is overvalued by 711.33% relative to our estimate of its Fair Value price of -$0.48 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NAGE ($2.95) is not significantly undervalued (711.33%) relative to our estimate of its Fair Value price of -$0.48 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NAGE is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NAGE due diligence checks available for Premium users.

Valuation

NAGE fair value

Fair Value of NAGE stock based on Discounted Cash Flow (DCF)

Price
$2.95
Fair Value
-$0.48
Undervalued by
711.33%
NAGE ($2.95) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NAGE ($2.95) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NAGE is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NAGE price to earnings (PE)

For valuing profitable companies with steady earnings

Company
14.75x
Industry
9.98x
Market
47.86x
NAGE is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NAGE is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

NAGE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.83x
Industry
5.25x
NAGE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NAGE's financial health

Profit margin

Revenue
$29.8M
Net Income
$963.0k
Profit Margin
3.2%
NAGE's Earnings (EBIT) of $17.03M... subscribe to Premium to read more.
Interest Coverage Financials
NAGE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$106.6M
Liabilities
$24.1M
Debt to equity
0.29
NAGE's short-term assets ($97.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NAGE's short-term assets ($97.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NAGE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NAGE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$2.8M
Investing
-$92.0k
Financing
-$2.5M
NAGE's operating cash flow ($5.95M)... subscribe to Premium to read more.
Debt Coverage Financials

NAGE vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
NAGEC$233.42M-1.01%14.75x2.83x
SIONF$232.84M+0.59%-2.37x0.88x
LYELC$235.98M-1.13%-0.75x1.01x
SLGLC$236.55M+4.03%-12.83x4.92x
LCTXC$239.76M-2.37%-6.77x3.94x

Niagen Bioscience Stock FAQ

What is Niagen Bioscience's quote symbol?

(NASDAQ: NAGE) Niagen Bioscience trades on the NASDAQ under the ticker symbol NAGE. Niagen Bioscience stock quotes can also be displayed as NASDAQ: NAGE.

If you're new to stock investing, here's how to buy Niagen Bioscience stock.

What is the 52 week high and low for Niagen Bioscience (NASDAQ: NAGE)?

(NASDAQ: NAGE) Niagen Bioscience's 52-week high was $9.28, and its 52-week low was $2.87. It is currently -68.21% from its 52-week high and 2.79% from its 52-week low.

How much is Niagen Bioscience stock worth today?

(NASDAQ: NAGE) Niagen Bioscience currently has 79,126,002 outstanding shares. With Niagen Bioscience stock trading at $2.95 per share, the total value of Niagen Bioscience stock (market capitalization) is $233.42M.

Niagen Bioscience stock was originally listed at a price of $11.70 in Jun 25, 2008. If you had invested in Niagen Bioscience stock at $11.70, your return over the last 18 years would have been -74.79%, for an annualized return of -7.37% (not including any dividends or dividend reinvestments).

How much is Niagen Bioscience's stock price per share?

(NASDAQ: NAGE) Niagen Bioscience stock price per share is $2.95 today (as of Sep 29, 2026).

What is Niagen Bioscience's Market Cap?

(NASDAQ: NAGE) Niagen Bioscience's market cap is $233.42M, as of Sep 30, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Niagen Bioscience's market cap is calculated by multiplying NAGE's current stock price of $2.95 by NAGE's total outstanding shares of 79,126,002.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.